Keywords: Merck & Co, EMA, CHMP, Remicade, Ulcertive colitis, Pediatric, EU

Merck & Co gets positive CHMP opinion for Remicade in new indication

Article | 22 January 2012

Print This

US drug giant Merck & Co (NYSE: MRK) says that announced that the European Medicines Agency’s Committee for ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in